<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/newsletter/style.css"/>
<title>ARS Pharmaceuticals announces real-world evidence on neffy effectiveness — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">ARS Pharmaceuticals announces real-world evidence on neffy effectiveness</h2>
    <div class="badge">2025-09-09T12:11:06+00:00</div>
    <ul>
      <li>Elevate Your Investing Strategy: - Take advantage of TipRanks Premium at 50% off!</li>
<li>Nearly 90% of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider.</li>
<li>Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of epinephrine intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis.</li>
<li>Try Now&gt;&gt; See Insiders’ Hot Stocks on TipRanks &gt;&gt; Read More on SPRY:</li>
<li>Importantly, these real-world data build upon previously published clinical evidence, including a prospective Phase 3 study assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis sym</li>
<li>Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.</li>
<li>In that study, no patients required a second dose of neffy for treatment of the initial anaphylactic reaction.</li>
    </ul>
    <p>
      <a class="btn" href="https://twitter.com/intent/tweet?text=ARS Pharmaceuticals announces real-world evidence on neffy effectiveness\n• Elevate Your Investing Strategy: - Take advantage of TipRanks Premium at 50% off!\n• Nearly 90% of 545 patients experiencing anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy by a healthcare provider.\n• Meta-analyses report a similar proportion of patients, 88.9%, being successfully treated with a single dose of epinephrine intramuscular injection or auto-injector by a healthcare provider for food-induced anaphylaxis.\n• Try Now&gt;&gt; See Insiders’ Hot Stocks on TipRanks &gt;&gt; Read More on SPRY:\n• Importantly, these real-world data build upon previously published clinical evidence, including a prospective Phase 3 study assessing the efficacy of neffy for the treatment of oral food challenge-induced anaphylaxis sym\n• Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news.\n• In that study, no patients required a second dose of neffy for treatment of the initial anaphylactic reaction." target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a href="https://finance.yahoo.com/news/ars-pharmaceuticals-announces-real-world-121106007.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>